TG Therapeutics | TGTX - Sales Revenues

Stock Price
28.88
Daily Change
1.12 4.03%
Monthly
-4.81%
Yearly
-12.72%
Q1 Forecast
28.52

TG Therapeutics reported $161.7M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 9.9B 340M Dec/2025
Ardelyx USD 110.33M 12.67M Sep/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Bayer EUR 9.66B 1.08B Sep/2025
Biogen USD 2.28B 250M Dec/2025
Corcept Therapeutics USD 207.6M 13.2M Sep/2025
Dynavax Technologies USD 94.9M 540K Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
J&J USD 24.6B 610M Dec/2025
Novartis USD 13.91B 144M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 161.7M 20.6M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025